Top 7 Equine Regenerative Therapies and Biologic Products in the United States (2025): Veterinary-Approved PRP, Stem Cell, ACS and Biologic Scaffold Options - Which 7 Leading Solutions American Vets Trust?

Arthrex ACP Double Syringe System is positioned as a best-in-class option for equine first aid because its simple closed double-syringe design enables rapid bedside preparation of platelet-rich plasma with minimal equipment, which keeps per-treatment costs low and logistics straightforward in field settings. Compared with filtration or tube-based competitors on this list, it trades some of the highest-yield laboratory performance for speed, ease of use and broader distribution — making it a practical, cost-effective choice for routine on-site wound and tendon management.

A portable, closed-loop point-of-care harvest and concentration platform optimized here for rapid mesenchymal stem cell (MSC) harvest in equine first-aid settings; its strength is bedside automation that shortens the time from tissue or blood collection to usable cell product, reducing labour and contamination risk compared with open manual methods. Financially, it lowers per-treatment turnaround and staffing costs for on-site clinics compared with larger laboratory-dependent systems, though it complements rather than replaces downstream defined culture kits and expansion bioreactors on this list.

Restigen PRP is presented as a best-in-class platelet-rich plasma option for equine first aid that prioritizes wound-healing and tissue-regeneration factors, delivered in a simple kit designed for field use and rapid deployment. Relative to cytokine-focused systems like IRAP II or APS, Restigen’s competitive advantage is lower per-treatment cost and logistical simplicity, though it offers less targeted anti‑inflammatory cytokine modulation; this makes it a practical choice for general soft-tissue injuries and practices seeking an affordable, portable regenerative tool. Its appeal is strongest where budget and immediacy of application outweigh the need for specialized anti‑inflammatory preparations.

MIMEDX EpiFix Equine represents the market-leading dHACM (dehydrated human amnion/chorion membrane) approach, prized for rich native growth factors and anti-inflammatory signals that can accelerate healing in complex or chronic equine wounds. Technically it often delivers faster biologic modulation than pure SIS or UBM scaffolds and may reduce overall treatment time, but it commands a premium price; it is typically chosen when clinical outcome acceleration outweighs per-unit cost compared with more economical ECM scaffolds such as VetBioSIS or Vetrix BioSIS.

Arthrex ACP is a widely adopted, user-friendly autologous conditioned plasma system valued in equine first aid for its quick bedside preparation and predictable growth factor profile that supports early-stage healing. Compared with more specialized cytokine-targeting systems like IRAP II, ACP offers a lower-cost, lower-complexity option that still delivers clinically meaningful platelet and plasma-derived growth factors for soft-tissue and superficial joint care. Its strength lies in broad availability, clear procedural protocols, and strong distributor support that together reduce the learning curve and per-treatment overhead for busy equine clinics.

CanEquine Regenerative Serum is a value-oriented regenerative serum leveraging pooled equine-derived factors to provide an affordable, widely available first-aid option for minor wounds and soft-tissue care. It typically has lower isolated exosome concentrations than dedicated exosome therapies but compensates with broad distribution and a lower acquisition cost, making it attractive to large stables and programs with tight budgets. Compared with premium offerings like VetBiotek or RegenEQ, CanEquine is positioned as the pragmatic, scalable choice for routine on-farm use rather than specialist clinical interventions.